Dual-Targeting Nanoplatform Based on Rolling Circle Amplification for Enhanced Multimodal Synergistic Treatment of Breast Cancer
Source abstract
Abstract
We present a rolling circle amplification (RCA)-based nanoplatform that integrates dual-targeting, photothermal therapy (PTT), chemodynamic therapy (CDT), gene therapy (GT), and chemotherapy (CT) for synergistic breast cancer therapy. First, RCA-assembly (RA) was constructed by integrating RCA and three single-stranded DNA (ssDNA) with different functions (S2.2 aptamer chain, 17-E DNAzyme chain, and carboxyl chain). Then, RA-Dox (RD) was further constructed based on the property of doxorubicin (Dox) autonomously binding to G–C bases. Finally, Fe 3 O 4 NPs modified with citrate and polydopamine nanoshell (CFO@PDA NPs) were loaded onto RD through an amidation reaction, which was named CFO@PDA@RD. In vitro MCF-7 cell experiments demonstrated that dual-targeting significantly enhanced the uptake of nanoplatform by MCF-7 cells. The nanoplatform not only has excellent photothermal performance but can also catalyze H 2 O 2 to generate hydroxyl radicals ( • OH) in situ and consume reduced glutathione (GSH) to diminish the antioxidant capacity of the tumor. Degradation of the nanoplatform resulted in the release of Fe 2+ for the activation of DNAzyme for the cleavage of miRNA-21 overexpressed in MCF-7 cells. In addition, the high loading and effective release of Dox by nanoplatform further endowed the nanoplatform with a chemotherapy effect. In summary, the CFO@PDA@RD nanoplatform with a multimodal synergistic treatment effect has great potential in breast cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry and Chemical Engineering, China University of Petroleum (East China), Qingdao 266580, China
Funding
Fundamental Research Funds for the Central Universities · Natural Science Foundation of Shandong Province
References (57)
Show source-provided references
1. 10.3390/jpm1108077110.3390/jpm11080771 ↗
2. 10.1021/acsapm.3c0204210.1021/acsapm.3c02042 ↗
3. 10.1016/j.jconrel.2020.09.03510.1016/j.jconrel.2020.09.035 ↗
4. 10.1002/smll.20220662410.1002/smll.202206624 ↗
5. 10.1039/D3TB02797J10.1039/D3TB02797J ↗
6. 10.1038/s41467-021-24961-510.1038/s41467-021-24961-5 ↗
7. 10.1016/j.mtchem.2023.10140010.1016/j.mtchem.2023.101400 ↗
8. 10.3390/ma1205077910.3390/ma12050779 ↗
9. 10.1063/5.004767210.1063/5.0047672 ↗
10. 10.1002/smll.20231215310.1002/smll.202312153 ↗
11. 10.1016/j.nantod.2020.10094610.1016/j.nantod.2020.100946 ↗
12. 10.3390/ijms24151200110.3390/ijms241512001 ↗
13. 10.7150/thno.4256410.7150/thno.42564 ↗
14. 10.1016/j.jconrel.2020.08.03610.1016/j.jconrel.2020.08.036 ↗
15. 10.1002/smll.20200396910.1002/smll.202003969 ↗
16. 10.1021/acs.analchem.9b0159110.1021/acs.analchem.9b01591 ↗
17. 10.1021/acsnano.9b0443610.1021/acsnano.9b04436 ↗
18. 10.1021/acsami.6b1120910.1021/acsami.6b11209 ↗
19. 10.1016/j.cis.2022.10268910.1016/j.cis.2022.102689 ↗
20. 10.1126/science.114724110.1126/science.1147241 ↗
21. 10.1016/j.jmst.2020.05.05510.1016/j.jmst.2020.05.055 ↗
22. 10.1016/j.bioactmat.2020.04.00310.1016/j.bioactmat.2020.04.003 ↗
23. 10.1002/adma.20120468310.1002/adma.201204683 ↗
24. 10.1021/acsami.1c2406610.1021/acsami.1c24066 ↗
25. 10.1021/am501391z10.1021/am501391z ↗
26. 10.1039/C5TB02784E10.1039/C5TB02784E ↗
27. 10.1016/j.actbio.2021.04.01910.1016/j.actbio.2021.04.019 ↗
28. 10.3390/polym1006057010.3390/polym10060570 ↗
29. 10.1002/adfm.20187023410.1002/adfm.201870234 ↗
30. 10.1016/j.actbio.2020.04.04110.1016/j.actbio.2020.04.041 ↗
31. 10.1038/s41573-019-0017-410.1038/s41573-019-0017-4 ↗
32. 10.1158/0008-5472.CAN-18-247410.1158/0008-5472.CAN-18-2474 ↗
33. 10.1016/j.ccr.2022.21465110.1016/j.ccr.2022.214651 ↗
34. 10.1038/s41573-021-00162-z10.1038/s41573-021-00162-z ↗
35. 10.1021/acs.nanolett.9b0178510.1021/acs.nanolett.9b01785 ↗
36. 10.1021/acsnano.9b0485710.1021/acsnano.9b04857 ↗
37. 10.1021/acsnano.7b0921010.1021/acsnano.7b09210 ↗
38. 10.1002/adfm.20160170310.1002/adfm.201601703 ↗
39. 10.1038/nbt.161810.1038/nbt.1618 ↗
40. 10.3390/cancers1404087210.3390/cancers14040872 ↗
41. 10.1002/smtd.20170031910.1002/smtd.201700319 ↗
42. 10.1038/am.2017.3410.1038/am.2017.34 ↗
43. 10.1021/acs.chemrev.0c0133210.1021/acs.chemrev.0c01332 ↗
44. 10.1039/c3cs60439j10.1039/c3cs60439j ↗
45. 10.1016/j.trac.2019.11570010.1016/j.trac.2019.115700 ↗
46. 10.1016/j.jcis.2021.11.03110.1016/j.jcis.2021.11.031 ↗
47. 10.1021/acsami.2c1039710.1021/acsami.2c10397 ↗
48. 10.1016/j.bios.2016.07.09510.1016/j.bios.2016.07.095 ↗
49. 10.1021/acsabm.9b0062210.1021/acsabm.9b00622 ↗
50. 10.1021/acs.analchem.0c0189510.1021/acs.analchem.0c01895 ↗
51. 10.1021/acs.nanolett.1c0172710.1021/acs.nanolett.1c01727 ↗
52. 10.1021/acsnano.1c0900810.1021/acsnano.1c09008 ↗
53. 10.1021/acsbiomaterials.0c0028810.1021/acsbiomaterials.0c00288 ↗
54. 10.1021/acs.biomac.2c0127110.1021/acs.biomac.2c01271 ↗
55. 10.1016/j.actbio.2019.02.03210.1016/j.actbio.2019.02.032 ↗
56. 10.1002/anie.20200365310.1002/anie.202003653 ↗
57. 10.1002/adfm.20200275310.1002/adfm.202002753 ↗